Cargando…
Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
Xeroderma Pigmentosum (XP) is a rare genetic disorder with a poor prognosis due to high photosensitivity in affected patients. Herein, we describe the first case of the use of cemiplimab in a patient with XP, a 19-year-old girl presented with locally advanced squamous cell carcinoma of the right per...
Autores principales: | Rubatto, Marco, Merli, Martina, Avallone, Gianluca, Agostini, Andrea, Mastorino, Luca, Caliendo, Virginia, Barcellini, Amelia, Vitolo, Viviana, Valvo, Francesca, Fierro, Maria Teresa, Ribero, Simone, Quaglino, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169062/ https://www.ncbi.nlm.nih.gov/pubmed/34084285 http://dx.doi.org/10.18632/oncotarget.27966 |
Ejemplares similares
-
Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022) -
Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
por: Boziou, Maria, et al.
Publicado: (2023) -
Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single‐centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course
por: Macagno, N., et al.
Publicado: (2022) -
Immunotherapy in transplanted patients: A special population that can no longer be ignored
por: Rubatto, Marco, et al.
Publicado: (2021) -
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022)